Exelixis EXEL
NASDAQ EXEL
$58.92 -0.21 (-0.35%)
As of: Sep 4, 2026 · 3:12 PM EDT

Exelixis (EXEL) Non Operating Interest Expenses (2010 - 2018)

Analysis

Exelixis (EXEL) Non Operating Interest Expenses (2010 - 2018) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Vertex Pharmaceuticals 138.58 Bn 130.73 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.33 Bn 77.33 Bn 3.93 Bn 11.00 Mn
3 Argenx Se 63.43 Bn 58.24 Bn 1.37 Bn -1.00 Mn
4 Moderna 57.84 Bn 52.70 Bn 52.00 Mn -
5 Revolution Medicines 44.01 Bn 44.01 Bn - 23.78 Mn
6 BeOne Medicines 39.93 Bn 34.83 Bn 1.53 Bn 39.74 Mn
7 Alnylam Pharmaceuticals 35.47 Bn 32.16 Bn 992.69 Mn 82.05 Mn
8 Royalty Pharma 28.39 Bn 27.56 Bn - 93.62 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 20.27 Mn
10 Exelixis 14.79 Bn 13.95 Bn 608.03 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 28, 2018 -1,000.00
Sep 28, 2018 1,000.00
Jun 30, 2017 4.26 Mn
Mar 31, 2017 4.42 Mn
Dec 30, 2016 4.49 Mn
Sep 30, 2016 7.83 Mn
Jun 30, 2016 10.45 Mn
Mar 31, 2016 10.29 Mn
Sep 30, 2015 10.04 Mn
Jun 30, 2015 11.96 Mn
Mar 31, 2015 12.40 Mn
Dec 31, 2014 5.24 Mn
Sep 30, 2014 12.28 Mn
Jun 30, 2014 12.08 Mn
Mar 31, 2014 11.76 Mn
Dec 31, 2013 5.05 Mn
Sep 30, 2013 11.43 Mn
Jun 30, 2013 11.24 Mn
Mar 31, 2013 11.06 Mn
Dec 31, 2012 9.00 Mn